^
Association details:
| Biomarker: | NFE2L2 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Pan-cancer analysis of NFE2L2 mutations identifies a subset of lung cancers with distinct genomic and improved immunotherapy outcomes
Published date:
10/04/2023
Excerpt:
CONTRADICTING EVIDENCE: Furthermore, in NSCLC and other cancer cohorts, patients with NFE2L2 mutation demonstrated more objective responses to ICIs than patients with wild type.
DOI:
https://doi.org/10.1186/s12935-023-03056-9
Source:
Title:
KEAP1/NFE2L2 as a prognostic biomarker on immunotherapy and correlation with immune infiltrates in non-small cell lung cancer (NSCLC).
Published date:
05/13/2020
Excerpt:
The OAK and POPLAR study cohort of NSCLC patients showed that KEAP1/NFE2L2 MUT was associated with poorer overall survival (OS), and progression-free survival (PFS) (OS: HR = 1.7, P < 0.001; PFS:HR = 1.4, P < 0.001) on immunotherapy, even after EGFR and ALK mutations were excluded, significant difference can also be gained (OS:HR = 1.8, P < 0.001; PFS:HR = 1.5, P < 0.001).
DOI:
10.1200/JCO.2020.38.15_suppl.e21551
Source:
Title:
Association of a STK11/KEAP1-mutation gene expression signature in lung adenocarcinoma with immune desertion in squamous cell carcinomas and mediation by NFE2L2 deregulation.
Published date:
05/13/2020
Excerpt:
A previously published cohort of NSCLC patients treated with ICI was analyzed for the predictive value of NFE2L2 mutations on PFS….In NSCLC, NFE2L2 mutations were associated with significantly worse PFS with ICI.
DOI:
10.1200/JCO.2020.38.15_suppl.3082
